<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles B Hicks, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Meredith Clement, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanne Marrazzo, MD, MPH, FACP, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Syphilis is an infection caused by the bacterium <em>Treponema pallidum</em>. Most new cases of syphilis are sexually acquired. The clinical manifestations depend upon the stage of disease. Studies performed in the preantibiotic era permit a relatively complete understanding of the natural history of untreated syphilis. Information about the natural history of untreated syphilis in humans derives from data collected from several sources:</p><p class="bulletIndent1"><span class="glyph">●</span>In the late 19<sup>th</sup> century, a Norwegian physician described the evolution of infection in more than 1400 patients with primary and secondary syphilis. Because he believed that the available therapies at the time were highly toxic and of little benefit, patients received no treatment [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional data were collected from a study of 382 adults with syphilis who underwent autopsies between 1917 and 1941 [<a href="#rid2">2</a>]. This compilation provided pathologic confirmation of the late manifestations of syphilis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Finally, the Tuskegee study conducted between 1932 and 1972 collected data on 431 Black men whose syphilis was untreated [<a href="#rid3">3</a>]. This project was initiated prior to the availability of effective therapy for syphilis, but it profoundly violated ethical standards by not providing study participants with treatment proven to be effective once it became available. Moreover, the study participants were not given sufficient information about the study to provide informed consent. These ethical concerns significantly impacted clinical research by engendering distrust between investigators and potential study participants that persists to this day; efforts to address these concerns have led to major reforms in clinical research standards and requirements. </p><p></p><p>The epidemiology, pathogenesis, and clinical manifestations of syphilis will be reviewed here. Discussions of the diagnosis and treatment of syphilis, as well as syphilis in special populations, are found elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4794.html" rel="external">"Syphilis in pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15400.html" rel="external">"Congenital syphilis: Management and outcome"</a>.)</p><p></p><p class="headingAnchor" id="H3705647768"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span><em>T. pallidum</em>, the causative organism of syphilis, was first identified in 1905 [<a href="#rid4">4</a>]. It is a bacterium from the order Spirochaetales and is one of several closely related treponemes that cause human disease [<a href="#rid5">5</a>]. <em>T. pallidum</em> is approximately 10 to 13 microns long but only 0.15 microns in width making it too slender to be visualized by direct microscopy. This feature greatly complicates diagnosis.</p><p>The organism can be seen with darkfield microscopy, a technique that employs a special condenser that casts an oblique light. When visualized by this method, <em>T. pallidum</em> is a delicate, corkscrew-shaped organism with tightly wound spirals  (<a class="graphic graphic_picture graphicRef56211" href="/d/graphic/56211.html" rel="external">picture 1</a>). It exhibits a characteristic rotary motion with flexing and back-and-forth movement, features considered sufficiently characteristic to be diagnostic [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H947750714"><span class="h1">EPIDEMIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Worldwide</strong> – The World Health Organization (WHO) estimates that worldwide in 2016 there were 19.9 million prevalent cases of syphilis in adolescents and adults aged 15 to 49 years and 6.3 million new cases [<a href="#rid7">7</a>]. As of 2014, the median case rate was 17.2 cases per 100,000 females and 17.7 cases per 100,000 males [<a href="#rid8">8</a>]. The highest prevalence was reported in the WHO Western Pacific region (93 cases per 100,000 adult population), followed by the African region (46.6 cases per 100,000 adult population), and the region of the Americas (34.1 cases per 100,000 adult population).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>United States</strong> – In the United States, syphilis has been a nationally notifiable disease since 1944. Its unique laboratory diagnostic features ensure that most cases are reported. Although there are relatively accurate statistics on the incidence of new infections [<a href="#rid9">9</a>], some data are still limited by missing demographic information. </p><p></p><p class="bulletIndent1">In the late 1980s and early 1990s, there was a mini epidemic of early syphilis that produced case rates that were higher than at any time since the introduction of penicillin in 1943. The number of cases peaked in 1990 (20.3 cases per 100,000 population) but subsequently fell to a new nadir in 2000, raising hopes for eradication [<a href="#rid10">10,11</a>]. However, the number of cases has continued to climb almost every year since that time  (<a class="graphic graphic_figure graphicRef138824" href="/d/graphic/138824.html" rel="external">figure 1</a>). In 2021, 176,713 cases of syphilis (all stages) were reported [<a href="#rid12">12</a>]. The total rate of syphilis increased approximately 32 percent during 2020 to 2021. The United States Centers for Disease Control and Prevention (CDC) states that the increased case counts seen in late-2020 and in 2021 may have been impacted by the COVID-19 pandemic and reflect an increase in health care utilization [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">In 2021, 53,767 cases of primary and secondary syphilis (the most infectious stages) were reported [<a href="#rid12">12</a>]. The rate of primary and secondary syphilis cases increased 28.6 percent from 2020 to 2021 with 16.2 cases per 100,000 population reported in 2021. Approximately 75 percent of primary and secondary syphilis cases occurred in men [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1">The rise in the rate of reported primary and secondary syphilis cases has been primarily attributable to increased cases in men who have sex with men (MSM)  (<a class="graphic graphic_figure graphicRef88975" href="/d/graphic/88975.html" rel="external">figure 2</a>) [<a href="#rid12">12</a>]. Gay, bisexual, and other MSM accounted for 46 percent of all male primary and secondary syphilis cases in 2021. Risk factors for acquisition of syphilis in MSM include methamphetamine use  (<a class="graphic graphic_figure graphicRef138825" href="/d/graphic/138825.html" rel="external">figure 3</a>) and having acquired recent sexual partners via social media [<a href="#rid14">14,15</a>]. </p><p></p><p class="bulletIndent1">Since 2012, the rate of primary and secondary syphilis in females has increased by over 700 percent, with an increase of 55 percent from 2020 to 2021 (4.7 to 7.3 cases per 100,00) [<a href="#rid12">12</a>]. The rate was higher in Black females compared with females of Hispanic ethnicity and White females (17.2, 6.1, and 4.8 per 100,000 population, respectively). A report from the United States CDC suggests that the increased rate of syphilis in females may be due in part to increased drug use [<a href="#rid16">16</a>]. In 2018, 29.3 percent of females with a diagnosis of primary or secondary syphilis reported recent injection drug use or use of heroin, methamphetamine, or crack/cocaine [<a href="#rid17">17</a>]. This rate of substance use was higher than in men who have sex with women or MSM diagnosed with primary and secondary syphilis (22.7 and 12.4 percent, respectively). </p><p></p><p class="bulletIndent1">With the increased number of cases in women, there has also been an increase in the number of cases of congenital syphilis. In 2021, 2855 cases of congenital syphilis were reported, including 220 congenital syphilis-related stillbirths and infant deaths [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/4794.html" rel="external">"Syphilis in pregnancy"</a> and  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Other epidemiologic trends include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is a high rate of human immunodeficiency virus (HIV) coinfection among MSM with syphilis. Available data from 2021 suggest that approximately 45 percent of MSM with primary and secondary syphilis have HIV, compared with about 7 percent of men who have sex with women and 4 percent of women [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/7600.html" rel="external">"Syphilis in patients with HIV", section on 'Epidemiology'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In men, the highest rates of primary and secondary syphilis in 2021 occurred in those aged 25 to 34 years  (<a class="graphic graphic_figure graphicRef138826" href="/d/graphic/138826.html" rel="external">figure 4</a>) [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The rate of reported primary and secondary syphilis cases remains highest among Black individuals, with the overall rate of syphilis being highest in Black men. As an example, in 2021, the rate of reported cases per 100,000 population was 68.3 in Black men, 27.8 in men of Hispanic ethnicity, and 13.4 in White men [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1">Late syphilis occurs in an uncertain proportion of patients infected by <em>T. pallidum</em>, with the uncertainty<em> </em>due to the lack of reliable systems for reporting late stages of the disease. However, there has also been an upward trend in late syphilis (including late latent syphilis) and syphilis of unknown duration, with the CDC reporting 9.4 cases per 100,000 in 2016 and 20.5 cases per 100,000 in 2020 [<a href="#rid12">12</a>]. This may be due in part to the resurgence in early syphilis that occurred in the United States in the late 1980s and early 1990s. Implementation of the reverse sequence screening method (ie, an initial treponemal test followed by a confirmatory nontreponemal test) in many labs across the country may also contribute to this upward trend in late and late latent syphilis cases. The reverse approach detects cases of late and late latent syphilis in patients whose nontreponemal test has become nonreactive over time. (See  <a class="medical medical_review" href="/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing", section on 'Serologic testing algorithms'</a>.)</p><p></p><p class="bulletIndent1">More detailed surveillance data can be found on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Fstatistics%2F2021%2Fdefault.htm&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLLB7P5JePSk9VhHpB%2BUI9lqHhbGN7yDdvZRHqOqGxZXxe9fWJ%2FXFkas2jV7q1D0T%2Bg%3D%3D&amp;TOPIC_ID=7584" target="_blank">CDC website</a>.</p><p></p><p class="headingAnchor" id="H971441096"><span class="h1">TRANSMISSION</span><span class="headingEndMark"> — </span>Transmission of <em>T. pallidum</em> usually occurs via direct contact with an infectious lesion during sex. In addition, <em>T. pallidum</em> readily crosses the placenta thereby resulting in fetal infection. The acquisition of syphilis through transfused blood is very rare because all donors are screened and <em>T. pallidum</em> cannot survive longer than 24 to 48 hours under blood bank storage conditions. Additional discussions of syphilis transmission during pregnancy and through blood donations are found elsewhere. (See  <a class="medical medical_review" href="/d/html/4794.html" rel="external">"Syphilis in pregnancy"</a> and  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Transmission'</a> and  <a class="medical medical_review" href="/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing", section on 'Syphilis'</a>.) </p><p>Sexual transmission requires exposure to open lesions with organisms present, features seen with the primary chancre and with some of the manifestations of secondary syphilis (mucous patches and condyloma lata). These lesions are very infectious, with an efficiency of transmission estimated at approximately 30 percent [<a href="#rid3">3,18</a>]. By contrast, the cutaneous lesions of secondary syphilis contain few treponemes, and the risk of transmission through intact skin is low. Patients with early latent syphilis are considered infectious due to concern for recently active lesions that are no longer present or active lesions that were missed on the initial evaluation.</p><p><em>T. pallidum</em> can initiate infection wherever inoculation occurs. Thus, contact of infected secretions with almost any tissue can lead to a primary syphilis lesion at that site, and syphilis can be spread by kissing or touching a person who has active lesions on the lips, oral cavity, breasts, or genitals. As an example, transmission of syphilis has been identified in men who have sex with men (MSM) who have reported oral sex as their only risk factor for acquisition [<a href="#rid19">19</a>]. Additional information on the pathophysiology of early infection is found below. (See <a class="local">'Early local infection'</a> below.)</p><p>Syphilis is also associated with the transmission and acquisition of other sexually transmitted infections (eg, HIV). As an example, in a study examining the HIV incidence among men with new primary and secondary syphilis, 1 in 20 MSM were diagnosed with HIV within one year of a syphilis diagnosis [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/7592.html" rel="external">"Approach to the patient with genital ulcers"</a> and  <a class="medical medical_review" href="/d/html/7600.html" rel="external">"Syphilis in patients with HIV", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The understanding of <em>T. pallidum</em> pathophysiology is impeded by the inability to grow the organism in culture. Thus, knowledge of the growth characteristics and metabolism of this bacterium are quite limited. Data in animal models and human subjects form the basis of most of the available information on this pathogen [<a href="#rid5">5,21</a>]. The pathogenesis of neurosyphilis is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7599.html" rel="external">"Neurosyphilis", section on 'Pathogenesis'</a>.) </p><p class="headingAnchor" id="H971441526"><span class="h2">Early local infection</span><span class="headingEndMark"> — </span><em>T. pallidum</em> initiates infection when it gains access to subcutaneous tissues via microscopic abrasions [<a href="#rid22">22</a>]. Despite a slow estimated dividing time of 30 hours, the spirochete evades early host immune responses and establishes the initial ulcerative lesion, the chancre  (<a class="graphic graphic_picture graphicRef75291" href="/d/graphic/75291.html" rel="external">picture 2</a>). During the period of early local replication, some organisms establish infection in regional draining lymph nodes with subsequent dissemination. </p><p><em>T. pallidum</em> elicits innate and adaptive cellular immune responses in skin and blood. The host immune response begins with lesional infiltration of polymorphonuclear leukocytes, which are soon replaced by T lymphocytes [<a href="#rid23">23</a>]. In one study of 23 patients with secondary syphilis, leukocytes were obtained from syphilitic lesions and peripheral blood mononuclear cells [<a href="#rid24">24</a>]. Compared with peripheral blood, lesional fluids were enriched with CD4+ and CD8+ T cells, activated monocytes, macrophages, and dendritic cells. Many of these dendritic cells also expressed HIV coreceptors (eg, CCR5 and DC-SIGN), which may help explain the epidemiologic link between syphilis and HIV transmission. (See  <a class="medical medical_review" href="/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents", section on 'Alterations in the CCR5 coreceptor'</a> and  <a class="medical medical_review" href="/d/html/7600.html" rel="external">"Syphilis in patients with HIV", section on 'Epidemiology'</a>.)</p><p>After acquisition of <em>T. pallidum</em>, humoral immune responses are also generated. This leads to the development of a variety of antibodies that can be detected relatively early in the course of syphilis. (See  <a class="medical medical_review" href="/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing"</a>.)</p><p>In some respects, the immune response to <em>T. pallidum</em> is paradoxical. On one hand, the various immune responses during early infection appear to be efficacious, since they coincide with resolution of the primary chancre, even in the absence of therapy. However, despite this apparent immune control, widespread dissemination of spirochetes occurs at the same time, leading to subsequent clinical manifestations of secondary or tertiary syphilis in untreated patients. (See <a class="local">'Clinical manifestations'</a> below.)</p><p class="headingAnchor" id="H971441534"><span class="h2">Late infection</span><span class="headingEndMark"> — </span>Cellular immunity is important for control of syphilis in experimental infection and probably contributes to the pathogenesis of late syphilis [<a href="#rid25">25</a>]. The prolonged latent period that is characteristic of most types of late syphilis suggests that immune mechanisms may be involved in one of two ways. Waning immunity with aging may facilitate recrudescence of a small number of treponemes that had survived in sequestered sites. Alternatively, a partially immune hypersensitive host may react to the presence of treponemes, engendering a chronic inflammatory response.</p><p>Gummas, or late benign syphilis often involving the skin, viscera, or other tissues (eg, bone, brain, abdominal viscera), are characterized pathologically by the presence of granulomas, a finding that is consistent with a cellular hypersensitivity reaction (see <a class="local">'Gummatous syphilis'</a> below). Experimental studies with human subjects who were inoculated cutaneously with live <em>T. pallidum</em> found that gummas developed only in those who had previous syphilis [<a href="#rid21">21</a>].This suggests that development of gummas requires an immune response insufficient to be protective but substantial enough to cause tissue damage and granuloma formation in the reinfected host. It is important to note that this study in human subjects was conducted in prisoners in the 1950s and was not subject to rigorous ethical review that would be expected in the current research landscape. </p><p>Cardiovascular syphilis with involvement of the ascending arch of the aorta and aortic valve is a consequence of vasculitis of the vasa vasorum ("endarteritis obliterans"). Small vessel vasculitis is a common manifestation of secondary and later stages of syphilis as evidenced by the presence of lymphocytes and plasma cells infiltrating blood vessels and perivascular tissues. </p><p class="headingAnchor" id="H3638352602"><span class="h1">STAGES OF DISEASE</span><span class="headingEndMark"> — </span>Patients with syphilis can present with a wide range of symptoms depending upon the stage of disease. Others will have serologic evidence of syphilis based upon laboratory testing but will not have symptoms (ie, latent syphilis). (See <a class="local">'Latent syphilis (asymptomatic)'</a> below.)</p><p>Syphilis is generally divided into early and late stages  (<a class="graphic graphic_table graphicRef50435" href="/d/graphic/50435.html" rel="external">table 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early syphilis</strong> – Early syphilis comprises primary and secondary syphilis, which typically occur within weeks to months after initial infection as well as early latent syphilis (asymptomatic infection that was acquired within the previous 12 months). (See <a class="local">'Primary syphilis (chancre)'</a> below and <a class="local">'Secondary syphilis'</a> below and <a class="local">'Latent syphilis (asymptomatic)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late syphilis</strong> – When patients are untreated during the earlier stages of syphilis, they can progress to late latent disease (which is asymptomatic) or develop major complications of the infection (eg, tertiary syphilis). The clinical events occurring as a consequence of late syphilis may appear at any time from 1 to 30 years after primary infection and can involve a wide variety of different tissues. (See <a class="local">'Late syphilis'</a> below.)</p><p></p><p>Patients can present with central nervous system (CNS) manifestations (neurosyphilis) at any time during the course of infection. A detailed discussion of neurosyphilis is found elsewhere. (See  <a class="medical medical_review" href="/d/html/7599.html" rel="external">"Neurosyphilis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with signs and symptoms consistent with syphilis should undergo serologic testing to confirm the diagnosis. However, certain patients can be treated empirically based upon the clinical findings (eg, patients with a suspected chancre and a known exposure). Discussions of the diagnosis and treatment of syphilis are found elsewhere. (See  <a class="medical medical_review" href="/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing"</a> and  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring"</a>.)</p><p class="headingAnchor" id="H3072912820"><span class="h2">Early syphilis</span></p><p class="headingAnchor" id="H9"><span class="h3">Primary syphilis (chancre)</span><span class="headingEndMark"> — </span>Following acquisition of <em>T. pallidum</em>, the initial clinical manifestation of infection is a localized skin lesion termed a chancre. The median incubation period before the chancre appears is 21 days (range 3 to 90 days) [<a href="#rid26">26</a>]. (See <a class="local">'Pathophysiology'</a> above.)</p><p>The lesion begins as a papule, which is typically (but not always) painless, appearing at the site of inoculation. This soon ulcerates to produce the classic chancre of primary syphilis, a 1 to 2 centimeter ulcer with a raised, indurated margin  (<a class="graphic graphic_picture graphicRef94890 graphicRef57637 graphicRef122594" href="/d/graphic/94890.html" rel="external">picture 3A-C</a>). The ulcer generally has a nonexudative base and is associated with mild to moderate regional lymphadenopathy that is often bilateral. Such lesions usually occur on the genitalia, but occasionally patients may develop chancres at other sites of inoculation  (<a class="graphic graphic_picture graphicRef82771" href="/d/graphic/82771.html" rel="external">picture 4</a>). These sites may include areas that may not be noticeable to the patient, including the posterior pharynx, anus, or vagina. Infrequently, multiple chancres occur, particularly in the setting of HIV infection. (See  <a class="medical medical_review" href="/d/html/7600.html" rel="external">"Syphilis in patients with HIV", section on 'Early syphilis'</a>.)</p><p>Chancres heal spontaneously within three to six weeks even in the absence of treatment. Since the ulcer is painless, many patients do not seek medical attention, a feature that enhances the likelihood of transmission. The mechanism of healing is unknown but is thought to be a consequence of local immune responses [<a href="#rid27">27</a>]. (See <a class="local">'Early local infection'</a> above.)</p><p>The chancre represents an initial local infection, but syphilis quickly becomes systemic with widespread dissemination of the spirochete. This dissemination may or may not be associated with concurrent systemic symptoms but is the pathophysiologic basis for subsequent secondary and/or late syphilis, including neurosyphilis. </p><p class="headingAnchor" id="H10"><span class="h3">Secondary syphilis</span><span class="headingEndMark"> — </span>Within weeks to a few months after the chancre develops, approximately 25 percent of individuals with untreated infection develop a systemic illness that represents secondary syphilis [<a href="#rid1">1</a>]. Patients with secondary syphilis may not have a history of a preceding chancre since the primary infection may have been asymptomatic and/or gone unnoticed. </p><p>Similar to primary disease, the acute manifestations of secondary syphilis typically resolve spontaneously, even in the absence of therapy, except in the case of severe cutaneous ulcerations called lues maligna  (<a class="graphic graphic_picture graphicRef122660 graphicRef122661 graphicRef50771" href="/d/graphic/122660.html" rel="external">picture 5A-C</a>). Occasionally, untreated patients experience additional episodes of relapsing secondary syphilis, which can occur for up to five years after their initial episode [<a href="#rid1">1</a>].</p><p>Secondary syphilis can produce a wide variety of signs and symptoms, which are described below.</p><p class="headingAnchor" id="H947754189"><span class="h4">Generalized symptoms</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constitutional symptoms</strong> – Patients with secondary syphilis may develop systemic symptoms including fever, headache, malaise, anorexia, sore throat, myalgias, and weight loss. These clinical manifestations probably reflect the brisk immunologic response resulting from widespread dissemination of <em>T. pallidum</em>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenopathy</strong> – Most patients with secondary syphilis have lymph node enlargement with palpable nodes present in the posterior cervical, axillary, inguinal, and femoral regions  (<a class="graphic graphic_picture graphicRef59275" href="/d/graphic/59275.html" rel="external">picture 6</a>). The finding of epitrochlear nodes is particularly suggestive of the diagnosis. These nodes are generally minimally tender, firm, and rubbery in consistency.</p><p></p><p class="headingAnchor" id="H947754114"><span class="h4">Dermatologic findings</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rash</strong> – Rash is the most characteristic finding of secondary syphilis. However, in one series of 105 patients with secondary syphilis, more than 20 percent had lesions that were not appreciated by the patient [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent1">The rash can take almost any form, although vesicular lesions are uncommon. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The rash is classically a diffuse, symmetric macular or papular eruption involving the entire trunk and extremities  (<a class="graphic graphic_picture graphicRef122595 graphicRef122597 graphicRef122598 graphicRef122599 graphicRef122601 graphicRef79451" href="/d/graphic/122595.html" rel="external">picture 7A-F</a>) including the palms and soles  (<a class="graphic graphic_picture graphicRef122602 graphicRef122603 graphicRef122605 graphicRef68877" href="/d/graphic/122602.html" rel="external">picture 8A-D</a>). Although involvement of the palms and soles is an important clue to the diagnosis of secondary syphilis, localized lesions can also occur [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent2">Individual lesions are discrete copper, red, or reddish-brown and measure 0.5 to 2 cm in diameter [<a href="#rid27">27,28</a>]. Although lesions are often scaly, they may be smooth. In addition, nodular lesions also may be seen. On occasion, the rash may be pruritic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pustular syphilis can take the form of small pustular syphilide, large pustular syphilide, flat pustular syphiloderm, and pustular-ulcerative syphilide (ie, malignant syphilis) [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Secondary syphilis can also affect mucosal surfaces [<a href="#rid28">28</a>]. Patients may develop mucous patches, whitish erosions on the oral mucosa or tongue  (<a class="graphic graphic_picture graphicRef66087 graphicRef52729 graphicRef72680" href="/d/graphic/66087.html" rel="external">picture 9A-C</a>), and split papules at the oral commissures. Large, raised, gray to white lesions called condylomata lata may develop in warm, moist areas such as the mouth and perineum  (<a class="graphic graphic_picture graphicRef83522 graphicRef56162 graphicRef122657 graphicRef122658" href="/d/graphic/83522.html" rel="external">picture 10A-D</a>). Condylomata lata occur most often in areas proximate to the primary chancre and may reflect direct spread of organisms from the primary ulcer [<a href="#rid27">27</a>]. Mucous patches and condylomata lata contain large numbers of <em>T. pallidum</em> organisms  (<a class="graphic graphic_picture graphicRef66008" href="/d/graphic/66008.html" rel="external">picture 11</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with HIV, a more severe ulcerative form of secondary syphilis termed "lues maligna" has been reported  (<a class="graphic graphic_picture graphicRef122660 graphicRef122661 graphicRef50771 graphicRef60313" href="/d/graphic/122660.html" rel="external">picture 5A-D</a>) [<a href="#rid30">30</a>]. It occurs principally in persons with severely compromised immune systems and presents with nonresolving severe ulcerative skin lesions. (See  <a class="medical medical_review" href="/d/html/7600.html" rel="external">"Syphilis in patients with HIV", section on 'Secondary syphilis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alopecia</strong> – So-called "moth-eaten" alopecia is occasionally seen among patients presenting with secondary syphilis  (<a class="graphic graphic_picture graphicRef52213 graphicRef122662 graphicRef122663" href="/d/graphic/52213.html" rel="external">picture 12A-C</a>). This may be noted on the scalp, eyebrows, or beard and is usually reversible with treatment.</p><p></p><p class="headingAnchor" id="H947754202"><span class="h4">Gastrointestinal findings</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis</strong> – Syphilitic hepatitis is characterized by a high-serum alkaline phosphatase level on laboratory examination, often with normal or only slightly abnormal transaminases [<a href="#rid31">31,32</a>]. Mild clinical hepatitis resolves with treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal abnormalities</strong> – The gastrointestinal tract may become extensively infiltrated or ulcerated; this can be misdiagnosed as lymphoma.</p><p></p><p class="headingAnchor" id="H947754341"><span class="h4">Musculoskeletal abnormalities</span><span class="headingEndMark"> — </span>Synovitis, osteitis, and periostitis can occur but usually resolve after treatment [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H947754361"><span class="h4">Renal abnormalities</span><span class="headingEndMark"> — </span>Patients with secondary syphilis can have mild transient albuminuria, nephrotic syndrome, or acute nephritis with hypertension and acute renal failure [<a href="#rid34">34</a>]. Pathologically, membranous glomerulonephritis or diffuse endocapillary glomerulonephritis, sometimes with crescents, can be seen. Resolution of renal abnormalities follows treatment for syphilis. </p><p class="headingAnchor" id="H3438073364"><span class="h3">Neurologic findings</span><span class="headingEndMark"> — </span>The early clinical manifestations of neurosyphilis are reviewed below and described in detail separately. (See  <a class="medical medical_review" href="/d/html/7599.html" rel="external">"Neurosyphilis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Headache</strong> – Invasion of the cerebrospinal fluid is common in early untreated disease, especially secondary syphilis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meninges and vascular manifestations</strong> – Patients may present with meningitis, cranial nerve deficits, meningovascular disease, or stroke. </p><p></p><p class="headingAnchor" id="H2687541926"><span class="h3">Visual/auditory findings</span><span class="headingEndMark"> — </span>Ocular or otic infection can occur at any stage of disease but is most commonly identified during the early stages [<a href="#rid35">35</a>]. Otosyphilis is diagnosed less often than ocular syphilis.</p><p>Although these findings can present with or without additional central nervous system (CNS) involvement, these types of infections are managed the same way as CNS infections. (See  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring", section on 'Treatment of neuro/ocular/otic syphilis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocular syphilis</strong> – A sometimes-underappreciated manifestation of syphilis is eye involvement, which has been increasingly reported in the last several years and may be more common among persons with HIV [<a href="#rid36">36-38</a>]. One report suggests ocular syphilis may be associated with certain strains of <em>T. pallidum</em> [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/7600.html" rel="external">"Syphilis in patients with HIV", section on 'Neurologic/ocular syphilis'</a>.)</p><p></p><p class="bulletIndent1">Patients can develop anterior uveitis, posterior uveitis, or panuveitis, which is often granulomatous. Most patients with ocular syphilis develop diminished visual acuity secondary to posterior uveitis  (<a class="graphic graphic_picture graphicRef68210" href="/d/graphic/68210.html" rel="external">picture 13</a>) [<a href="#rid36">36,40</a>]. Posterior uveitis typically presents as multifocal chorioretinitis; however, other manifestations include retinal necrosis and optic neuritis. </p><p></p><p class="bulletIndent1">Involvement of the eye in patients with syphilis should be evaluated and managed emergently, especially when retinal involvement is present. Vision loss can occur with ocular syphilis and may be rapidly progressive; however, it can be prevented or minimized with early therapy. (See  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring", section on 'Treatment of neuro/ocular/otic syphilis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Otosyphilis</strong> – Otosyphilis typically presents with cochleo-vestibular symptoms, such as tinnitus, vertigo, and sensorineural hearing loss [<a href="#rid35">35</a>]. Hearing loss can have a sudden onset and be unilateral or bilateral. Symptoms can progress rapidly and in some patients may result in permanent hearing loss. </p><p></p><p class="headingAnchor" id="H12"><span class="h2">Late syphilis</span><span class="headingEndMark"> — </span>Approximately 25 to 40 percent of patients with untreated syphilis can develop late disease. The clinical events may appear at any time from 1 to 30 years after primary infection [<a href="#rid2">2</a>]. It is not necessary for individuals to have experienced clinically symptomatic primary or secondary syphilis prior to developing late syphilis.</p><p>The clinical manifestations of late syphilis are highly variable and may involve a wide variety of different tissues. However, a strong index of suspicion is essential for the proper clinical diagnosis since the classic descriptions may be altered by antimicrobial therapy administered for other diagnoses. </p><p>The most common manifestations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular syphilis (especially aortitis)</p><p class="bulletIndent1"><span class="glyph">●</span>Gummatous syphilis (granulomatous, nodular lesions that are rare, can occur in a variety of organs, usually skin and bones)</p><p class="bulletIndent1"><span class="glyph">●</span>CNS involvement (particularly general paresis and tabes dorsalis)</p><p></p><p>A confirmed case of late syphilis with clinical manifestations requires the demonstration of <em>T. pallidum</em> in late syphilitic lesions by special stains (eg, Warthin-Starry silver and immunofluorescent staining), polymerase chain reaction, or equivalent direct molecular methods. A probable case is diagnosed when characteristic abnormalities or lesions are noted along with a reactive treponemal serological test. A detailed discussion of diagnostic testing for syphilis is found elsewhere. (See  <a class="medical medical_review" href="/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing"</a> and  <a class="medical medical_review" href="/d/html/7599.html" rel="external">"Neurosyphilis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2503918501"><span class="h3">Tertiary syphilis</span><span class="headingEndMark"> — </span>Tertiary syphilis describes patients with late syphilis who have symptomatic manifestations involving the cardiovascular system or gummatous disease (granulomatous disease of the skin and subcutaneous tissues, bones, or viscera).</p><p class="headingAnchor" id="H947752135"><span class="h4">Cardiovascular</span><span class="headingEndMark"> — </span>Cardiovascular syphilis classically involves the ascending thoracic aorta resulting in a dilated aorta and aortic valve regurgitation. The disorder is thought to be a consequence of vasculitis in the vasa vasorum leading to a weakening of the wall of the aortic root [<a href="#rid41">41</a>]. The onset is typically insidious; most patients present with an asymptomatic murmur or with left heart failure. Clinical manifestations typically occur 15 to 30 years from initial infection in the untreated patient. Syphilitic aneurysms rarely lead to dissection.</p><p>Physical examination may reveal a high-pitched "tambour" second sound, but this finding is neither specific nor sensitive. Chest films often show a calcified ascending arch of the aorta, reflecting the chronic inflammation of the intima; this finding is not usually seen in arteriosclerotic disease  (<a class="graphic graphic_diagnosticimage graphicRef82736" href="/d/graphic/82736.html" rel="external">image 1</a>). Syphilis may also involve the coronary arteries, resulting in coronary artery narrowing and thrombosis. Coronary ostial stenosis may sometimes be found on catheterization [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H2244594218"><span class="h4">Gummatous syphilis</span><span class="headingEndMark"> — </span>Gummatous syphilis is very uncommon. However, several cases of gummas have been reported in individuals with HIV. Most of these have involved internal organs. (See  <a class="medical medical_review" href="/d/html/7600.html" rel="external">"Syphilis in patients with HIV", section on 'Neurosyphilis'</a>.)</p><p>Gummas can occur anywhere, including skin, bones, or internal organs. On the skin, gummas may present as ulcers or heaped up granulomatous lesions with a round, irregular, or serpiginous shape  (<a class="graphic graphic_picture graphicRef122678 graphicRef104182" href="/d/graphic/122678.html" rel="external">picture 14A-B</a>). They range from small to very large and may be severe in malnourished individuals ("rupial" lesions). Visceral gummas may present as a mass lesion. If a biopsy shows granulomas, lesions may be mistaken for a number of other diseases, including sarcoidosis, which is characterized by granulomas. (See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/3582.html" rel="external">"Evaluation of the adult patient with hepatic granuloma"</a>.)</p><p class="headingAnchor" id="H333972472"><span class="h3">Central nervous system</span><span class="headingEndMark"> — </span>There are many forms of CNS syphilis, some of which may occur as many as 25 years after the initial infection (eg, general paresis and tabes dorsalis). A detailed discussion of the CNS manifestations of late-stage syphilis is found elsewhere. (See  <a class="medical medical_review" href="/d/html/7599.html" rel="external">"Neurosyphilis", section on 'Late neurosyphilis'</a>.)</p><p class="headingAnchor" id="H947752771"><span class="h1">LATENT SYPHILIS (ASYMPTOMATIC)</span><span class="headingEndMark"> — </span>Latent syphilis refers to the period when a patient is infected with <em>T. pallidum</em> (as demonstrated by serologic testing) but has <strong>no </strong>symptoms. The diagnosis of latent syphilis is based only upon the results of serological testing, which is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing", section on 'Latent syphilis'</a>.) </p><p>Latent syphilis is typically divided into early (if initial infection occurred within the previous 12 months) and late (if initial infection occurred &gt;12 months ago) [<a href="#rid9">9</a>]. If the timing of an infection is not known, late latent syphilis is presumed. </p><p>It is important to differentiate between early and late latent syphilis to understand the risk of transmission to others. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with late latent disease are not considered infectious to their recent sexual contacts since they do not have lesions that can transmit disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, patients with early latent syphilis may have transmitted <em>T. pallidum</em> to their sexual partners through lesions that were recently active but are no longer present. It is also possible that patients with early latent syphilis were not diagnosed because of an obscure or painless lesion that was present but not discovered on physical exam. (See <a class="local">'Primary syphilis (chancre)'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant women with latent syphilis can transmit <em>T. pallidum</em> to their fetus for up to four years after acquisition. (See  <a class="medical medical_review" href="/d/html/4794.html" rel="external">"Syphilis in pregnancy"</a> and  <a class="medical medical_review" href="/d/html/15400.html" rel="external">"Congenital syphilis: Management and outcome"</a>.) </p><p></p><p>Differentiating early from late latent disease also has implications for treatment (eg, one versus three doses of intramuscular [IM] <a class="drug drug_general" data-topicid="9551" href="/d/drug information/9551.html" rel="external">penicillin G benzathine</a>)  (<a class="graphic graphic_table graphicRef50435" href="/d/graphic/50435.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring", section on 'Treatment of early syphilis'</a> and  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring", section on 'Treatment of late syphilis'</a>.)</p><p class="headingAnchor" id="H114489647"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H24752446"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/17045.html" rel="external">"Patient education: Syphilis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15132379"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – Syphilis is an infection caused by the bacterium <em>Treponema pallidum</em>. <em>T. pallidum</em> is a delicate, corkscrew-shaped organism with tightly wound spirals, which exhibits a characteristic rotary motion seen on darkfield microscopy. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The number of cases of syphilis in the United States has been increasing. The increase in rates of primary and secondary syphilis has occurred among both men and women in every region of the country. Syphilis also remains an important problem in other areas of the world. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission</strong> – Virtually all new syphilis infections are sexually acquired via contact with mucocutaneous syphilitic lesions, except for cases resulting from vertical transmission (ie, infection acquired in utero or during delivery). Syphilis is transmissible during primary or secondary syphilis with an efficiency of transmission estimated at approximately 30 percent. Patients with early latent syphilis are considered infectious due to lesions that were recently active but are no longer present or were missed on the initial evaluation. (See <a class="local">'Transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – <em>T. pallidum</em> gains access to subcutaneous tissues via microscopic abrasions. Despite a slow estimated dividing time of 30 hours, the spirochete evades early host immune responses and establishes the initial ulcerative lesion (the chancre). During the period of early local replication, some organisms establish infection in regional draining lymph nodes with subsequent dissemination. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with syphilis can present with a wide range of signs and symptoms depending upon the stage of disease (primary, secondary, tertiary)  (<a class="graphic graphic_table graphicRef50435" href="/d/graphic/50435.html" rel="external">table 1</a>). These include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary syphilis</strong> – Following acquisition of <em>T. pallidum</em>, the initial clinical manifestations of primary syphilis consist of a painless chancre at the site of inoculation, which usually heals within a few weeks, even if untreated  (<a class="graphic graphic_picture graphicRef94890 graphicRef57637 graphicRef122594" href="/d/graphic/94890.html" rel="external">picture 3A-C</a>). (See <a class="local">'Primary syphilis (chancre)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary syphilis</strong> – Weeks to months later, approximately 25 percent of individuals with untreated primary infection develop secondary syphilis, which is characterized by systemic symptoms including fever, rash, headache, malaise, anorexia, and diffuse lymphadenopathy  (<a class="graphic graphic_picture graphicRef122595 graphicRef122597 graphicRef122598 graphicRef122599 graphicRef122601 graphicRef79451" href="/d/graphic/122595.html" rel="external">picture 7A-F</a>). (See <a class="local">'Secondary syphilis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Late syphilis</strong> – When patients are untreated during the earlier stages of syphilis, they are at risk for major complications involving the central nervous system (CNS), cardiovascular structures, or skin and bones  (<a class="graphic graphic_picture graphicRef122678 graphicRef104182" href="/d/graphic/122678.html" rel="external">picture 14A-B</a>). (See <a class="local">'Late syphilis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurosyphilis</strong> – Neurosyphilis can occur at any time following infection. A detailed discussion of neurosyphilis is presented in a separate topic review. (See  <a class="medical medical_review" href="/d/html/7599.html" rel="external">"Neurosyphilis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Latent syphilis</strong> – Latent syphilis refers to the period when a patient is infected with <em>T. pallidum</em> (as demonstrated by serologic testing) but has <strong>no</strong> symptoms. Latent syphilis is typically divided into early (if initial infection occurred within the previous 12 months) and late (if initial infection occurred &gt;12 months ago). If the timing of an infection is not known, late latent syphilis is presumed. (See <a class="local">'Stages of disease'</a> above and <a class="local">'Latent syphilis (asymptomatic)'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges P Frederick Sparling, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Clark EG, Danbolt N. The Oslo study of the natural course of untreated syphilis: An epidemiologic investigation based on a re-study of the Boeck-Bruusgaard material. Med Clin North Am 1964; 48:613.</a></li><li class="breakAll">Rosahn PD. Autopsy studies in syphilis. 649 Information supplement #21, J Venereal Disease; U.S. Public Health Service Venereal Disease Division, Washington, DC 1947.</li><li><a class="nounderline abstract_t">ROCKWELL DH, YOBS AR, MOORE MB Jr. THE TUSKEGEE STUDY OF UNTREATED SYPHILIS; THE 30TH YEAR OF OBSERVATION. Arch Intern Med 1964; 114:792.</a></li><li><a class="nounderline abstract_t">Schaudinn FR, Hoffmann E. Vorlaufiger bericht uber das vorkommen von spirochaeten in syphilitischen krakheitsproducten und bei papillomen. Arbeiten aus dem K gesundheitsamte 1905; 22:527.</a></li><li class="breakAll">Musher DM. Biology of Treponema pallidum. In: Sexually Transmitted Diseases, Holmes KK, Mardh PA, Sparling PF, et al (Eds), McGraw-Hill, New York 1990. p.205.</li><li><a class="nounderline abstract_t">Larsen SA. Syphilis. Clin Lab Med 1989; 9:545.</a></li><li><a class="nounderline abstract_t">Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ 2019; 97:548.</a></li><li class="breakAll">World Health Organization. Report on globally sexually transmitted infection surveillance, 2015. http://apps.who.int/iris/bitstream/handle/10665/249553/9789241565301-eng.pdf;jsessionid=25DA348EE7CDFC387C271F7767AFD756?sequence=1a (Accessed on May 16, 2018).</li><li class="breakAll">Centers for Disease Control and Prevention. Syphilis (Treponema pallidum) 2018 Case Definition. https://ndc.services.cdc.gov/case-definitions/syphilis-2018/ (Accessed on June 17, 2021).</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Primary and secondary syphilis--United States, 1998. MMWR Morb Mortal Wkly Rep 1999; 48:873.</a></li><li><a class="nounderline abstract_t">Mitka M. US effort to eliminate syphilis moving forward. JAMA 2000; 283:1555.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2021. Available at: https://www.cdc.gov/std/statistics/2021/tables/19.htm (Accessed on June 20, 2023).</li><li class="breakAll">United States Centers for Disease Control and Prevention. Impacrt of COVID-19 on STDs. https://www.cdc.gov/std/statistics/2021/impact.htm (Accessed on December 19, 2023).</li><li><a class="nounderline abstract_t">Wong W, Chaw JK, Kent CK, Klausner JD. Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003. Sex Transm Dis 2005; 32:458.</a></li><li><a class="nounderline abstract_t">Landovitz RJ, Tseng CH, Weissman M, et al. Epidemiology, sexual risk behavior, and HIV prevention practices of men who have sex with men using GRINDR in Los Angeles, California. J Urban Health 2013; 90:729.</a></li><li><a class="nounderline abstract_t">Kidd SE, Grey JA, Torrone EA, Weinstock HS. Increased Methamphetamine, Injection Drug, and Heroin Use Among Women and Heterosexual Men with Primary and Secondary Syphilis - United States, 2013-2017. MMWR Morb Mortal Wkly Rep 2019; 68:144.</a></li><li><a class="nounderline abstract_t">Copen CE, Brookmeyer KA, Haderxhanaj LT, et al. Sexual Risk Behaviors Among Persons Diagnosed With Primary and Secondary Syphilis Who Reported High-Risk Substance Use: Data From the National Notifiable Diseases Surveillance System, 2018. Sex Transm Dis 2022; 49:99.</a></li><li><a class="nounderline abstract_t">Hook EW 3rd, Marra CM. Acquired syphilis in adults. N Engl J Med 1992; 326:1060.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Transmission of primary and secondary syphilis by oral sex--Chicago, Illinois, 1998-2002. MMWR Morb Mortal Wkly Rep 2004; 53:966.</a></li><li><a class="nounderline abstract_t">Pathela P, Braunstein SL, Blank S, et al. The high risk of an HIV diagnosis following a diagnosis of syphilis: a population-level analysis of New York City men. Clin Infect Dis 2015; 61:281.</a></li><li><a class="nounderline abstract_t">MAGNUSON HJ, THOMAS EW, OLANSKY S, et al. Inoculation syphilis in human volunteers. Medicine (Baltimore) 1956; 35:33.</a></li><li><a class="nounderline abstract_t">French P. Syphilis. BMJ 2007; 334:143.</a></li><li><a class="nounderline abstract_t">Baker-Zander S, Sell S. A histopathologic and immunologic study of the course of syphilis in the experimentally infected rabbit. Demonstration of long-lasting cellular immunity. Am J Pathol 1980; 101:387.</a></li><li><a class="nounderline abstract_t">Salazar JC, Cruz AR, Pope CD, et al. Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis. J Infect Dis 2007; 195:879.</a></li><li class="breakAll">Wicher, K, et al. Immunopathology of syphilis. In: Pathogenesis and Immunology of Treponemal Infection, Schell, RF, et al (Eds), Marcel Dekker, 1983. p.61.</li><li class="breakAll">Sparling PF. Natural history of syphilis. In: Sexually Transmitted Diseases, Holmes KK, Mardh PA, Sparling PF, et al (Eds), McGraw-Hill, New York 1990. p.213.</li><li class="breakAll">Musher D. Early syphilis. In: Sexually Transmitted Diseases, Holmes KK, Sparling PF, Mardh PA (Eds), McGraw-Hill, New York 1999. p.479.</li><li><a class="nounderline abstract_t">Chapel TA. The signs and symptoms of secondary syphilis. Sex Transm Dis 1980; 7:161.</a></li><li><a class="nounderline abstract_t">Pleimes M, Hartschuh W, Kutzner H, et al. Malignant syphilis with ocular involvement and organism-depleted lesions. Clin Infect Dis 2009; 48:83.</a></li><li><a class="nounderline abstract_t">D'Amico R, Zalusky R. A case of lues maligna in a patient with acquired immunodeficiency syndrome (AIDS). Scand J Infect Dis 2005; 37:697.</a></li><li><a class="nounderline abstract_t">Young MF, Sanowski RA, Manne RA. Syphilitic hepatitis. J Clin Gastroenterol 1992; 15:174.</a></li><li><a class="nounderline abstract_t">Ferrándiz-Pulido C, Ferrer B, Salcedo MT, et al. Secondary syphilis with liver involvement in a liver transplant recipient. Transpl Infect Dis 2021; 23:e13431.</a></li><li><a class="nounderline abstract_t">Reginato AJ. Syphilitic arthritis and osteitis. Rheum Dis Clin North Am 1993; 19:379.</a></li><li><a class="nounderline abstract_t">Hunte W, al-Ghraoui F, Cohen RJ. Secondary syphilis and the nephrotic syndrome. J Am Soc Nephrol 1993; 3:1351.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Balba GP, Kumar PN, James AN, et al. Ocular syphilis in HIV-positive patients receiving highly active antiretroviral therapy. Am J Med 2006; 119:448.e21.</a></li><li><a class="nounderline abstract_t">Westeneng AC, Rothova A, de Boer JH, de Groot-Mijnes JD. Infectious uveitis in immunocompromised patients and the diagnostic value of polymerase chain reaction and Goldmann-Witmer coefficient in aqueous analysis. Am J Ophthalmol 2007; 144:781.</a></li><li><a class="nounderline abstract_t">Oliver SE, Aubin M, Atwell L, et al. Ocular Syphilis - Eight Jurisdictions, United States, 2014-2015. MMWR Morb Mortal Wkly Rep 2016; 65:1185.</a></li><li><a class="nounderline abstract_t">Nettleton WD, Kent JB, Lightheart K, Diesel JC. A Cluster of Ocular Syphilis Cases with a Common Sex Partner - Southwest Michigan, 2022. MMWR Morb Mortal Wkly Rep 2023; 72:1281.</a></li><li><a class="nounderline abstract_t">Durnian JM, Naylor G, Saeed AM. Ocular syphilis: the return of an old acquaintance. Eye (Lond) 2004; 18:440.</a></li><li><a class="nounderline abstract_t">Kennedy JL, Barnard JJ, Prahlow JA. Syphilitic coronary artery ostial stenosis resulting in acute myocardial infarction and death. Cardiology 2006; 105:25.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-1998. A 46-year-old man with chest pain and coronary ostial stenosis. N Engl J Med 1998; 338:897.</a></li></ol></div><div id="topicVersionRevision">Topic 7584 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The Oslo study of the natural course of untreated syphilis: An epidemiologic investigation based on a re-study of the Boeck-Bruusgaard material</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Oslo study of the natural course of untreated syphilis: An epidemiologic investigation based on a re-study of the Boeck-Bruusgaard material</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14211593" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : THE TUSKEGEE STUDY OF UNTREATED SYPHILIS; THE 30TH YEAR OF OBSERVATION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Vorlaufiger bericht uber das vorkommen von spirochaeten in syphilitischen krakheitsproducten und bei papillomen</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Vorlaufiger bericht uber das vorkommen von spirochaeten in syphilitischen krakheitsproducten und bei papillomen</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2676323" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31384073" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31384073" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31384073" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10550037" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Primary and secondary syphilis--United States, 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735376" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : US effort to eliminate syphilis moving forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735376" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : US effort to eliminate syphilis moving forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735376" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : US effort to eliminate syphilis moving forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15976605" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22983721" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Epidemiology, sexual risk behavior, and HIV prevention practices of men who have sex with men using GRINDR in Los Angeles, California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763294" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Increased Methamphetamine, Injection Drug, and Heroin Use Among Women and Heterosexual Men with Primary and Secondary Syphilis - United States, 2013-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34475356" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sexual Risk Behaviors Among Persons Diagnosed With Primary and Secondary Syphilis Who Reported High-Risk Substance Use: Data From the National Notifiable Diseases Surveillance System, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1549153" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acquired syphilis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496825" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Transmission of primary and secondary syphilis by oral sex--Chicago, Illinois, 1998-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25870333" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The high risk of an HIV diagnosis following a diagnosis of syphilis: a population-level analysis of New York City men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13296652" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Inoculation syphilis in human volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17235095" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7001910" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A histopathologic and immunologic study of the course of syphilis in the experimentally infected rabbit. Demonstration of long-lasting cellular immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299719" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299719" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299719" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299719" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7455863" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The signs and symptoms of secondary syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035775" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Malignant syphilis with ocular involvement and organism-depleted lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16126575" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A case of lues maligna in a patient with acquired immunodeficiency syndrome (AIDS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1401840" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Syphilitic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32738832" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Secondary syphilis with liver involvement in a liver transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8502778" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Syphilitic arthritis and osteitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8439646" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Secondary syphilis and the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16651059" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ocular syphilis in HIV-positive patients receiving highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17707328" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Infectious uveitis in immunocompromised patients and the diagnostic value of polymerase chain reaction and Goldmann-Witmer coefficient in aqueous analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27811837" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Ocular Syphilis - Eight Jurisdictions, United States, 2014-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37991986" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A Cluster of Ocular Syphilis Cases with a Common Sex Partner - Southwest Michigan, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15069449" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ocular syphilis: the return of an old acquaintance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16179782" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Syphilitic coronary artery ostial stenosis resulting in acute myocardial infarction and death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9518283" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-1998. A 46-year-old man with chest pain and coronary ostial stenosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
